Ignite Creation Date:
2024-05-06 @ 7:35 PM
Last Modification Date:
2024-10-26 @ 3:10 PM
Study NCT ID:
NCT06068543
Status:
RECRUITING
Last Update Posted:
2024-04-10
First Post:
2023-09-20
Brief Title:
Reducing Frailty for Older Cancer Survivors Using Supplements II
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate EGCG on Frailty and Inflammation in Older Survivors of Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ReFOCUS2
Brief Summary:
This study is a two-arm placebo controlled randomized clinical trial to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None